K
Karla V. Ballman
Researcher at Cornell University
Publications - 390
Citations - 34158
Karla V. Ballman is an academic researcher from Cornell University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 78, co-authored 353 publications receiving 29127 citations. Previous affiliations of Karla V. Ballman include University of South Florida & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial
Armando E. Giuliano,Kelly K. Hunt,Karla V. Ballman,Peter D. Beitsch,Pat Whitworth,Peter W. Blumencranz,A. Marilyn Leitch,Sukamal Saha,Linda M. McCall,Monica Morrow +9 more
TL;DR: Among patients with limited SLN metastatic breast cancer treated with breast conservation and systemic therapy, the use of SLND alone compared with ALND did not result in inferior survival, and overall survival was the primary end point, with a noninferiority margin of a 1-sided hazard ratio of less than 1.3 indicating thatSLND alone is noninherited.
Journal ArticleDOI
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Ronald P. DeMatteo,Karla V. Ballman,Cristina R. Antonescu,Robert G. Maki,Peter W.T. Pisters,George D. Demetri,Martin E. Blackstein,Charles D. Blanke,Margaret von Mehren,Murray F. Brennan,Shreyaskumar Patel,Martin D. McCarter,Jonathan Polikoff,Benjamin R. Tan,Kouros Owzar +14 more
TL;DR: Adjuvant imatinib therapy is safe and seems to improve recurrence-free survival compared with placebo after the resection of primary gastrointestinal stromal tumour.
Journal ArticleDOI
Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial
Paul D. Brown,Kurt A. Jaeckle,Karla V. Ballman,Elana Farace,Jane H. Cerhan,S. Keith Anderson,Xiomara W. Carrero,Fred G. Barker,Richard L. Deming,Stuart H. Burri,Cynthia Ménard,Cynthia Ménard,Caroline Chung,Volker W. Stieber,Bruce E. Pollock,Evanthia Galanis,Jan C. Buckner,Anthony L. Asher +17 more
TL;DR: Among patients with 1 to 3 brain metastases, the use of SRS alone, compared with SRS combined with WBRT, resulted in less cognitive deterioration at 3 months, and in the absence of a difference in overall survival, these findings suggest that.
Journal ArticleDOI
Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial.
Armando E. Giuliano,Linda M. McCall,Peter D. Beitsch,Pat Whitworth,Peter W. Blumencranz,A. Marilyn Leitch,Sukamal Saha,Kelly K. Hunt,Monica Morrow,Karla V. Ballman +9 more
TL;DR: Despite the potential for residual axillary disease after SLND, SLND without ALND can offer excellent regional control and may be reasonable management for selected patients with early-stage breast cancer treated with breast-conserving therapy and adjuvant systemic therapy.
Journal ArticleDOI
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial
Armando E. Giuliano,Karla V. Ballman,Linda M. McCall,Peter D. Beitsch,Meghan Brennan,Pond R. Kelemen,David W. Ollila,Nora M. Hansen,Pat Whitworth,Peter W. Blumencranz,A. Marilyn Leitch,Sukamal Saha,Kelly K. Hunt,Monica Morrow +13 more
TL;DR: Findings do not support routine use of axillary lymph node dissection in this patient population based on 10-year outcomes, and overall survival for patients treated with sentinel lymph nodes dissection alone was noninferior toOverall survival for those treated with axillary node dissections.